Methods and reagents for diagnosing rheumatoid arthrtis
AssigneeAbbott Japan Co., Ltd.
InventorsToru Yoshimura, Ryotaro Chiba
Life of this patent
Estimating the term…
Loading patent…
AssigneeAbbott Japan Co., Ltd.
InventorsToru Yoshimura, Ryotaro Chiba
Estimating the term…
Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.
A method for diagnosing rheumatoid arthritis in a subject comprising measuring the level of CCL8 protein in a test sample obtained from the subject wherein the level of CCL8 protein in the test sample indicates presence or absence of rheumatoid arthritis in the subject.
A method for determining the severity of rheumatoid arthritis in a subject comprising determining the presence or absence of an elevated level of CCL8 protein in a test sample obtained from the subject wherein the presence of an elevated level of CCL8 protein indicates that the rheumatoid arthritis in the subject is severe.
A diagnostic reagent for rheumatoid arthritis comprising an anti-CCL8 antibody or fragment thereof, and an antibody against at least one marker of rheumatoid arthritis selected from the group consisting of:
A method for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis, comprising:
The use of an anti-CCL8 antibody or fragment thereof as a diagnostic reagent for the diagnosis of rheumatoid arthritis in a subject.
The use of an anti-CCL8 antibody or fragment thereof as an active ingredient in a pharmaceutical composition for the treatment of rheumatoid arthritis in a subject.
The use of an anti-CCL8 antibody or fragment thereof in the manufacture of a reagent for the diagnosis of rheumatoid arthritis in a subject.
The use of an anti-CCL8 antibody or fragment thereof in the manufacture of a pharmaceutical composition for the treatment of rheumatoid arthritis in a subject.
A method for monitoring the effect of a treatment of rheumatoid arthritis in a subject comprising:
Dependencies are inferred from the claim text.